Baseline characteristics

Study of Dovitinib and Biomarkers in Advanced Non-Small Cell Lung Cancer or Advanced Colorectal Cancer · Source last updated 2018-01-10

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      10

   units

   Participants

groups

1. description

   500 mg of dovitinib (5 capsules) once a day for 5 continuous days and stop for 2 days. Continue to take dovitinib capsules in this manner until until progression or unacceptable toxicity develops. Dovitinib

   id

   BG000

   title

   Dovitinib

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            48

            upper Limit

            77

            value

            63

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            5

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            5

         title

         Male

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

3. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            10

      title

      United States

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Region of Enrollment

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice